Nurix Therapeutics (NRIX) Competitors

Nurix Therapeutics (NASDAQ:NRIX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.

Which has higher valuation and earnings, NRIX or KRYS?

Krystal Biotech has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$56.42M	17.07	-$193.57M	-$2.80	-4.51
Krystal Biotech	$333.45M	12.10	$10.93M	$4.16	33.56

Do analysts rate NRIX or KRYS?

Nurix Therapeutics currently has a consensus price target of $30.18, indicating a potential upside of 138.93%. Krystal Biotech has a consensus price target of $211.13, indicating a potential upside of 51.21%. Given Nurix Therapeutics' higher probable upside, equities analysts plainly believe Nurix Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.83
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of NRIX or KRYS?

86.3% of Krystal Biotech shares are owned by institutional investors. 7.4% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more risk and volatility, NRIX or KRYS?

Nurix Therapeutics has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Does the media refer more to NRIX or KRYS?

In the previous week, Krystal Biotech had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Krystal Biotech and 5 mentions for Nurix Therapeutics. Krystal Biotech's average media sentiment score of 1.07 beat Nurix Therapeutics' score of 0.58 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer NRIX or KRYS?

Krystal Biotech received 213 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 78.18% of users gave Nurix Therapeutics an outperform vote while only 67.80% of users gave Krystal Biotech an outperform vote.

Company	Underperform	Outperform
Nurix Therapeutics	Outperform Votes 86 78.18%	Underperform Votes 24 21.82%
Krystal Biotech	Outperform Votes 299 67.80%	Underperform Votes 142 32.20%

Is NRIX or KRYS more profitable?

Krystal Biotech has a net margin of 30.69% compared to Nurix Therapeutics' net margin of -354.85%. Krystal Biotech's return on equity of 11.41% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-354.85%	-53.65%	-38.59%
Krystal Biotech	30.69%	11.41%	10.40%

Summary

Krystal Biotech beats Nurix Therapeutics on 14 of the 19 factors compared between the two stocks.